Daily pill shrank a rare joint tumour in over half of patients
The FDA approved Pimjetmi (pimicotinib) for tenosynovial giant cell tumour after the MANEUVER trial, where tumours shrank substantially in 56% of patients against 3.2% on placebo.

Contents
- What is tenosynovial giant cell tumour?
- What exactly did the FDA approve?
- How does pimicotinib work?
- What did the MANEUVER trial find?
- Do the responses last?
- What are the side effects?
- How does it compare with Turalio and Romvimza?
- Is pimicotinib available in the UK or Europe?
- What should people with TGCT ask their specialist?
- What happens next?
A once-daily pill called pimicotinib is now approved in the United States for tenosynovial giant cell tumour (TGCT), a rare growth in or around a joint. The US Food and Drug Administration approved it on 10 November 2026 under the brand name Pimjetmi. In the phase 3 trial behind the decision, tumours shrank substantially in 56% of people on the drug after 25 weeks, against 3.2% on placebo.
It is the third drug of its type cleared by the FDA for this disease. What sets it apart, on the trial data so far, is a combination of a high response rate, once-a-day dosing and no cases of the serious bile-duct liver injury that has dogged an older drug in the same class. Those claims come with caveats, and the trial was never designed to compare pimicotinib with the other two medicines.
What is tenosynovial giant cell tumour?
TGCT grows from the lining of joints, tendon sheaths and the small fluid-filled sacs (bursae) that cushion them. It is classed as a benign tumour because it almost never spreads to other organs. That label undersells the problem. The tumour can wrap around a joint, eat into cartilage and bone, and cause pain, swelling, stiffness and locking.
The Lancet paper reporting the main trial describes it as a rare, locally aggressive tumour that affects otherwise healthy adults. In the trial, the median age was 40, and 68% of participants were women. Half had the tumour in a knee, with ankles and hips the next most common sites.
Doctors split TGCT into a localised form, a single nodule that surgery can often remove, and a diffuse form that spreads through the joint lining. The diffuse form is the one that keeps coming back. Some people have had several operations on the same knee and still have disease.
Diagnosis is often slow. In its approval announcement, Merck KGaA, Darmstadt, Germany cites a patient registry study reporting that up to half of people with TGCT may first be misdiagnosed. Knee symptoms get blamed on sports injuries or arthritis until an MRI scan shows the tumour.
What exactly did the FDA approve?
The approval covers adults with symptomatic TGCT for whom surgery to remove the tumour may cause worsening functional limitation or severe morbidity. In plain terms, it is for people whose tumour is causing symptoms and where an operation would be likely to leave the joint worse off, or would not get all the disease out.
The dose is 50 mg taken by mouth once a day, with or without food. Pimjetmi is sold in the US by EMD Serono, the name Merck KGaA, Darmstadt, Germany uses for its healthcare business in the US and Canada. The drug was discovered by Abbisko Therapeutics in Shanghai, which licensed worldwide commercial rights to Merck KGaA.
The FDA reviewed the application with fast track and breakthrough therapy designations. It also ran the review under Project Orbis, an FDA scheme in which several regulators look at a cancer drug at the same time. The partners this time were Australia's Therapeutic Goods Administration, Health Canada, Israel's Ministry of Health, Swissmedic and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), with the European Medicines Agency (EMA) observing.
According to Abbisko's announcement, the US decision is the drug's fourth approval. China approved it in December 2025, Canada in June 2026 and Switzerland in October 2026.
How does pimicotinib work?
TGCT is driven by a protein called colony-stimulating factor 1 (CSF-1). In most tumours, a small number of cells carry a genetic rearrangement that makes them churn out CSF-1. That signal pulls in large numbers of immune cells, mainly macrophages, which carry the receptor for CSF-1 (CSF-1R). Those recruited cells make up most of the tumour mass.
Pimicotinib is a small-molecule drug that blocks CSF-1R. Cut the signal and the recruited cells stop gathering and multiplying, so the tumour shrinks. The same idea lies behind the two earlier approved drugs, pexidartinib (Turalio) and vimseltinib (Romvimza). Abbisko describes pimicotinib as highly selective for CSF-1R, which in theory means fewer effects on other kinases.
What did the MANEUVER trial find?
MANEUVER (NCT05804045) enrolled 94 adults at 40 hospitals in Asia, Europe and North America between April 2023 and March 2024. Everyone had symptomatic TGCT that was not suitable for surgery, with worst pain or stiffness rated at least 4 out of 10. Nobody had taken a CSF-1 or CSF-1R drug before. Patients were randomly assigned, two to one, to pimicotinib (63 people) or a matching placebo (31 people) for 24 weeks. Neither patients nor doctors knew who was getting what.
The main measure was the share of people whose tumour shrank by at least 30% on MRI by week 25, judged by radiologists who did not know the treatment assignment. That is called the objective response rate. The trial also tracked how far people could move the affected joint, how bad their pain and stiffness were, and how well they could do everyday physical tasks.
Results were first presented at the ASCO Annual Meeting in 2025 and published in The Lancet on 5 March 2026, with Hairong Xu and Xiaohui Niu of Beijing Jishuitan Hospital as lead authors. The main findings at week 25:
| Measure at week 25 | Pimicotinib (63) | Placebo (31) |
|---|---|---|
| Tumour shrank by 30% or more (FDA analysis) | 56% | 3.2% |
| Tumour shrank by 30% or more (Lancet paper) | 54% (34 people) | 3% (1 person) |
| Response by tumour volume score | 62% (39 people) | 3% (1 person) |
| Complete response, tumour gone on MRI (Lancet) | 1 person | 0 |
| Any tumour shrinkage (Lancet) | 92% | 71% |
| Pain eased by at least 30% (ASCO abstract) | 63.5% | 16.1% |
You may notice two figures for the main result. The Lancet paper reports 54% (34 of 63). The FDA's own review put it at 56%, with a 95% confidence interval of 42% to 68%. Regulators often redo the analysis themselves, and small differences like this are common. Either way, the gap with placebo is large and the p value was below 0.0001.
Responses came early. At the first scan, at week 13, 26 people on pimicotinib (41%) already met the response threshold.
The symptom results all went the same way. Average range of motion in the affected joint improved by about 15.6 percentage points on pimicotinib, against almost no change on placebo, according to the ASCO 2025 abstract. Worst pain fell by 2.3 points on a 0 to 10 scale on the drug, compared with 0.2 points on placebo. Stiffness and physical function scores also improved more on the drug, and every one of these key secondary endpoints was statistically significant.
Do the responses last?
The early signs are encouraging, though follow-up is still short. In a longer analysis presented at the ESMO Congress in October 2025, with a median of 14.3 months of follow-up, 76.2% of people who started on pimicotinib had responded at some point. Four had a complete response. The median length of response had not been reached.
The FDA's summary puts it more conservatively. Of the 35 responders it counted, 32 (91%) stayed in response for at least six months and 27 (77%) for at least 12 months. People who started on placebo and switched to pimicotinib after week 25 also responded, with 64.5% meeting the threshold after a median of about eight and a half months on the drug.
What nobody knows yet is what happens after people stop. CSF-1R drugs block the signal that feeds the tumour without removing the genetic change that started it, so it is not yet clear how often tumours regrow once treatment ends. MANEUVER's long-term extension phase should help answer that.
What are the side effects?
The most common side effects on the US label, each affecting more than 20% of people, are itching, rash, swelling of the face, swelling around the eyes, tiredness, nausea, headache and swelling of the hands and feet. Many people also had raised blood levels of enzymes such as creatine phosphokinase, lactate dehydrogenase, liver enzymes (AST and ALT), lipase and amylase, along with higher cholesterol.
Most of these were mild in the trial. In the Lancet paper, the only severe (grade 3 or 4) side effect seen in more than 10% of people on the drug was raised creatine phosphokinase, in 8 of 63 (13%). Five people (8%) needed a lower dose. One person (2%) stopped because of side effects.
The label carries warnings for liver toxicity, harm to an unborn baby, and a rise in serum creatinine that does not reflect real kidney damage. EMD Serono's US press release says liver blood tests are needed before starting, every month for the first three months, then every three months for the rest of the first year. People who can become pregnant need effective contraception during treatment and for two weeks afterwards.
The trial reported no cholestatic liver injury, no drug-induced liver injury, and no lightening of skin or hair, a known effect of some drugs in this class. With 63 people treated in the randomised phase, rare problems would be easy to miss. Wider use will show more.
How does it compare with Turalio and Romvimza?
Three CSF-1R drugs now have US approval for TGCT. There has been no head-to-head trial, and the three main trials differed in design, size and who they enrolled. Comparing response rates across trials is risky, and these figures should be read as rough context only.
| Pexidartinib (Turalio) | Vimseltinib (Romvimza) | Pimicotinib (Pimjetmi) | |
|---|---|---|---|
| FDA approval | 2019 | February 2025 | November 2026 |
| Dosing | 250 mg twice daily with a low-fat meal | 30 mg twice a week | 50 mg once daily |
| Main trial | ENLIVEN (120 people) | MOTION (123 people) | MANEUVER (94 people) |
| Week 25 response vs placebo (FDA label or notice) | 38% vs 0% | 40% vs 0% | 56% vs 3.2% |
| Boxed liver warning | Yes, with restricted access programme | No | No |
The Turalio label carries a boxed warning for serious and potentially fatal liver injury, including vanishing bile duct syndrome, and the drug can only be prescribed through a restricted programme (a REMS). In its main trial, ENLIVEN, 38% of people on Turalio responded at week 25, against none on placebo. The FDA's approval notice for vimseltinib reported a 40% response rate in MOTION, and the FDA decided that drug did not need a boxed warning either.
The MANEUVER figure is higher than both. That does not prove pimicotinib works better. MANEUVER enrolled almost half its patients in China, and its population may differ from MOTION's in ways that affect response. Choice between the drugs will come down to dosing, side effects, cost and insurance coverage, and what a person's specialist has experience with.
Is pimicotinib available in the UK or Europe?
Not yet, as of mid-November 2026. The MHRA took part in the Project Orbis review, and the EMA observed it, but neither has announced a decision in the sources we reviewed. The EMA has given pimicotinib PRIME status, its scheme for medicines that may meet a major unmet need.
In the EU, vimseltinib is already authorised. The European Commission approved Romvimza on 17 September 2025, according to its EMA product page. Pexidartinib has never been approved there. The EMA refused Turalio in 2020, judging that modest symptom benefits did not outweigh the liver risk.
For anyone outside the US, clinical trials remain a route to newer TGCT drugs. Our guide on how to find and join a clinical trial explains where to search and what to ask.
What should people with TGCT ask their specialist?
Surgery is still the first option for many people, especially with the localised form. A drug like pimicotinib is aimed at people whose tumour cannot be removed cleanly, or who face repeated operations that could damage the joint. These questions may help in a conversation with a sarcoma or orthopaedic oncology team:
- Is my tumour localised or diffuse, and what would surgery realistically achieve?
- Do I meet the approved use, meaning surgery could worsen my function or cause serious problems?
- Which CSF-1R drug would you suggest for me, and why?
- How often will I need liver blood tests and MRI scans?
- How long would I take it, and what happens if I stop?
- Am I eligible for any trials if I live outside the US?
It also helps to know how to read a trial result. A 56% response rate means just over half of people had substantial shrinkage on MRI. It does not mean the tumour disappears for most people; complete disappearance was rare. Our explainer on how to read clinical trial results covers this kind of figure, and our guide to placebo and blinding explains why a 3.2% placebo response matters for interpreting the result.
What happens next?
MANEUVER is continuing, with patients in the open-label extension being followed for longer-term benefit and safety. Abbisko says it will receive a milestone payment from Merck KGaA on the first US commercial sale. Regulatory decisions from the other Project Orbis partners, including the UK, could follow in the coming months, though no dates have been announced.
For more on how US, UK and European approvals differ, see our guide on how new medicines get approved by the FDA, MHRA and NICE. Other recent cancer approvals on the site include dostarlimab for rectal cancer and amivantamab for head and neck cancer.
This article is for information only and is not medical advice. Anyone with TGCT should talk to their own specialist about whether pimicotinib or another treatment is right for them.
Frequently asked questions
What is Pimjetmi approved for?
On 10 November 2026 the FDA approved Pimjetmi (pimicotinib) for adults with symptomatic tenosynovial giant cell tumour (TGCT) where surgery may worsen how the joint works or cause severe problems. It is a 50 mg tablet taken once a day, with or without food. The approval applies to the United States only.
How well did pimicotinib work in the MANEUVER trial?
After 25 weeks, tumours shrank by at least 30% on MRI in 56% of people on pimicotinib in the FDA's analysis, compared with 3.2% on placebo. The published Lancet paper gives 54% (34 of 63). People on the drug also reported less pain and stiffness and could move the affected joint further.
Is pimicotinib better than Turalio or Romvimza?
Nobody knows. No trial has compared the three drugs directly, and their main trials enrolled different groups of people. MANEUVER's week 25 response rate was higher than those reported for Turalio (38%) and Romvimza (40%), but cross-trial comparisons are unreliable. Dosing and side-effect profiles also differ, which may guide the choice.
What are the main side effects of pimicotinib?
The most common were itching, rash, facial swelling, swelling around the eyes, tiredness, nausea, headache and swelling of the hands and feet. Raised blood enzymes were frequent. The label warns about liver toxicity and harm to an unborn baby, so liver blood tests are needed before and during treatment. In the trial, one person in 63 stopped because of side effects.
Can I get pimicotinib in the UK or EU?
Not as of mid-November 2026. The UK's MHRA took part in the joint Project Orbis review and the EMA observed it, but no UK or EU decision had been announced in the sources we reviewed. In the EU, vimseltinib (Romvimza) is already authorised for TGCT. Clinical trials are another possible route to newer drugs.
Sources
- FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor. US Food and Drug Administration, 2026-11-10
- FDA Approves PIMJETMI (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor. Merck KGaA, Darmstadt, Germany, 2026-11-10
- FDA Approves PIMJETMI (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor (US press release). EMD Serono, 2026-11-10
- PIMJETMI (pimicotinib) developed by Abbisko Therapeutics and licensed by Merck KGaA, Darmstadt, Germany receive US FDA approval for TGCT. Abbisko Therapeutics via PR Newswire, 2026-11-10
- Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial (Xu H, Niu X, et al.). The Lancet, 2026-03-05
- Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER), abstract, PMID 41796601. PubMed, 2026-03-14
- Pimicotinib in TGCT: efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study (ASCO 2025 abstract 11500). Journal of Clinical Oncology, 2025-06-01
- Extended efficacy and safety from the phase 3 MANEUVER trial of pimicotinib in TGCT (ESMO 2025 presentation, Niu X, et al.). EMD Serono Medical, 2025-10-17
- A Study of Pimicotinib in Patients With Tenosynovial Giant Cell Tumor (MANEUVER), NCT05804045. ClinicalTrials.gov, 2026-11-16
- FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor. US Food and Drug Administration, 2025-02-14
- TURALIO (pexidartinib) prescribing information. US Food and Drug Administration, 2025-01-01
- Romvimza (vimseltinib) EPAR. European Medicines Agency, 2025-09-17
- Turalio (pexidartinib) refusal of marketing authorisation. European Medicines Agency, 2020-06-25
- tenosynovial giant cell tumour
- Pimjetmi
- FDA approval
- Abbisko Therapeutics
- TGCT
- MANEUVER
- EMD Serono
- rare tumours
- pimicotinib
- CSF-1R inhibitor
- Merck KGaA
- The Lancet
Medical disclaimer: For information only, not medical advice. Speak to a qualified healthcare professional about your care.
The Briefing
Trial results that matter, every Friday.
One email. The week's readouts, approvals and research, explained without hype.
Related reading
OncologyImmunotherapy alone beat chemo for a common type of womb cancer
26 October 2026
OncologyTwo-pill combination helped lung cancer patients outlive chemo
25 October 2026
OncologyNew lung cancer pill beats older KRAS drugs in head-to-head trial
25 October 2026
Tarlatamab extends small cell lung cancer survival by 8 months
24 October 2026